APA

Hosten B., Challuau D., Gil S., Bouquet C., Marion S., Perricaudet M., Di Palma M., Farinotti R. & Bonhomme-Faivre L. (20060627). Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma. : Anti-cancer drugs.

Chicago

Hosten Benoît, Challuau Désiré, Gil Sophie, Bouquet Céline, Marion Sylvie, Perricaudet Michel, Di Palma Mario, Farinotti Robert and Bonhomme-Faivre Laurence. 20060627. Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma. : Anti-cancer drugs.

Harvard

Hosten B., Challuau D., Gil S., Bouquet C., Marion S., Perricaudet M., Di Palma M., Farinotti R. and Bonhomme-Faivre L. (20060627). Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma. : Anti-cancer drugs.

MLA

Hosten Benoît, Challuau Désiré, Gil Sophie, Bouquet Céline, Marion Sylvie, Perricaudet Michel, Di Palma Mario, Farinotti Robert and Bonhomme-Faivre Laurence. Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma. : Anti-cancer drugs. 20060627.